Opinion|Videos|July 29, 2024
How Experts View MAIC Data That was Presented at EHA 2024
A panel of experts examines and interprets the most recent matching-adjusted indirect comparison (MAIC) data presented at the European Hematology Association 2024 conference, focusing on the comparative analysis of the ASCEND and ALPINE trials in chronic lymphocytic leukemia treatment.
Advertisement
Episodes in this series
- Briefly discuss key data from the latest MAIC data presented at EHA 2024:
- MAIC: ASCEND vs ALPINE –
Shadman, et al. EHA 2024. Abstract P700 - How do these data compare to those previously reportedcomparing ASCEND and ALPINE data? (
Kittai A, et al. ASCO 2023. Abstract 7540 )
- How do these data compare to those previously reportedcomparing ASCEND and ALPINE data? (
- MAIC: ASCEND vs ALPINE –
- How do you interpret these findings and other available MAIC data and what further insights do they provide?
- What guidance can you offer community oncologists about incorporating MAIC data in treatment decisions?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 that may shake up the CLL treatment paradigm.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
4
How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC
5